INM 089
Alternative Names: INM-089Latest Information Update: 25 Jan 2024
At a glance
- Originator InMed Pharmaceuticals
- Class Cannabinoids; Eye disorder therapies; Neuroprotectants
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Age-related macular degeneration
Most Recent Events
- 16 Jan 2024 InMed Pharmaceuticals files an IND application for Age-related Macular Degeneration in 1H 2025
- 21 Dec 2023 Preclinical trials in Age-related macular degeneration in Canada (Topical)
- 29 Nov 2023 InMed Pharmaceuticals plans an IND-enabling toxicology studies (InMed Pharmaceuticals pipeline, November 2023)